Alector's Phase 3 Trial Results Fail to Meet Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Should l Buy ALEC?
Source: PRnewswire
- Trial Results: Alector's Phase 3 INFRONT-3 trial evaluating latozinemab showed that while the biomarker response met expectations, the clinical co-primary endpoint was not achieved, leading to investor disappointment.
- Participant Demographics: The trial enrolled 119 patients, including 103 symptomatic FTD-GRN individuals and 16 at-risk carriers, with a mean age of 62.1 years, indicating the drug's potential application in a specific demographic.
- Market Reaction: Following the mixed trial results, analysts downgraded Alector's stock, reflecting market concerns about its biotech operations, which may impact the company's future financing capabilities.
- Legal Investigation: Levi & Korsinsky, LLP is investigating Alector, highlighting investor concerns regarding the company's operational performance, which could lead to further legal actions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALEC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALEC
Wall Street analysts forecast ALEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALEC is 2.10 USD with a low forecast of 0.90 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
1 Buy
5 Hold
2 Sell
Hold
Current: 1.820
Low
0.90
Averages
2.10
High
5.00
Current: 1.820
Low
0.90
Averages
2.10
High
5.00
About ALEC
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alector's Phase 3 Trial Results Fail to Meet Expectations
- Trial Results: Alector's Phase 3 INFRONT-3 trial evaluating latozinemab showed that while the biomarker response met expectations, the clinical co-primary endpoint was not achieved, leading to investor disappointment.
- Participant Demographics: The trial enrolled 119 patients, including 103 symptomatic FTD-GRN individuals and 16 at-risk carriers, with a mean age of 62.1 years, indicating the drug's potential application in a specific demographic.
- Market Reaction: Following the mixed trial results, analysts downgraded Alector's stock, reflecting market concerns about its biotech operations, which may impact the company's future financing capabilities.
- Legal Investigation: Levi & Korsinsky, LLP is investigating Alector, highlighting investor concerns regarding the company's operational performance, which could lead to further legal actions.
See More
Alector Appoints Neil Berkley as CFO, Strengthening Leadership Amid Strategic Growth
- Leadership Transition: Alector announced Neil Berkley's official appointment as CFO effective December 10, 2025, while he continues as CBO, reflecting the company's high regard for his leadership and strategic insight.
- Extensive Experience: With over 20 years in the biotech industry, Berkley has held significant roles in large pharmaceutical and biotech firms, providing Alector with deep support in finance and operations.
- Strategic Priorities: Since joining Alector in 2024, Berkley has played a key role in advancing the company's strategic priorities, strengthening partnerships, and supporting value creation, ensuring robust progress during this critical growth phase.
- Integration of Science and Business: Berkley expressed his commitment to supporting the company's scientific and corporate priorities in neurodegenerative diseases, particularly in advancing promising pipeline products and the development of the ABC platform, aimed at improving patient outcomes and reducing costs.
See More
Alector Appoints Neil Berkley as CFO to Drive Biotech Strategy
- Executive Appointment: Alector announced Neil Berkley's official appointment as Chief Financial Officer (CFO) effective December 10, 2025, after serving as Chief Business Officer (CBO) since March 2024 and Interim CFO since June 2025, reflecting the company's high regard for his leadership capabilities.
- Strategic Leadership: With over 20 years of experience in the biotech sector, Berkley's extensive background in large pharmaceutical and mid-sized biotech firms positions him to effectively drive Alector's strategic priorities in developing therapies for neurodegenerative diseases.
- Financing and Development: Berkley's rich experience in financing, investor engagement, and corporate development will support Alector's key value-creation initiatives, particularly in advancing its promising pipeline and proprietary ABC platform.
- Company Vision: Berkley expressed his commitment to supporting Alector's scientific and corporate priorities, aiming to develop transformative therapies for patients with neurodegenerative diseases, thereby enhancing the company's competitive edge in the market.
See More
Alector Appoints Neil Berkley as CFO
New CFO Appointment: Alector Inc. has announced that Neil Berkley will become the new Chief Financial Officer starting December 10, 2025, while also retaining his role as Chief Business Officer.
Experience and Background: Berkley has over 20 years of experience in corporate strategy, finance, business development, and operations within the biotech and pharmaceutical industries.
Stock Performance: Alector's stock closed at $1.49, reflecting an increase of $0.03 or 2.05 percent on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily represent those of Nasdaq, Inc.
See More
Alector Shares Plunge Nearly 50% Following Phase 3 Trial Failure
- Legal Investigation Initiated: The Schall Law Firm is investigating Alector for potential violations of securities laws, particularly regarding the issuance of false or misleading statements, indicating significant legal risks for the company.
- Poor Clinical Trial Results: Alector's October 21, 2025 press release revealed that its drug candidate, latozinemab, failed to meet the primary clinical endpoint of slowing frontotemporal dementia progression, directly impacting investor confidence in the company's future prospects.
- Stock Price Volatility: Following the disappointing clinical trial results, Alector's shares plummeted nearly 50% the next day, reflecting market pessimism about the company's outlook and raising concerns about its financial health among investors.
- Investor Rights Affected: This incident has drawn attention to the rights of Alector's investors, with the Schall Law Firm urging affected shareholders to participate in the investigation, highlighting potential deficiencies in the company's transparency and information disclosure practices.
See More
ALEC Investors Can Participate in Alector, Inc. Fraud Investigation Led by the Schall Law Firm
Investigation Announcement: The Schall Law Firm is investigating Alector, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors.
Clinical Trial Results: Alector's recent press release revealed that its drug candidate, latozinemab, failed to meet key clinical trial endpoints for treating frontotemporal dementia, leading to a significant drop in the company's stock price.
Investor Impact: Following the announcement of the clinical trial results, Alector's shares plummeted by nearly 50% the day after the news was released.
Legal Support Offer: The Schall Law Firm is offering free consultations to shareholders who may have suffered losses and encourages them to reach out for assistance regarding their rights.
See More
Alector's Phase 3 Trial Results Fail to Meet Expectations
- Trial Results: Alector's Phase 3 INFRONT-3 trial evaluating latozinemab showed that while the biomarker response met expectations, the clinical co-primary endpoint was not achieved, leading to investor disappointment.
- Participant Demographics: The trial enrolled 119 patients, including 103 symptomatic FTD-GRN individuals and 16 at-risk carriers, with a mean age of 62.1 years, indicating the drug's potential application in a specific demographic.
- Market Reaction: Following the mixed trial results, analysts downgraded Alector's stock, reflecting market concerns about its biotech operations, which may impact the company's future financing capabilities.
- Legal Investigation: Levi & Korsinsky, LLP is investigating Alector, highlighting investor concerns regarding the company's operational performance, which could lead to further legal actions.
See More
Alector Appoints Neil Berkley as CFO, Strengthening Leadership Amid Strategic Growth
- Leadership Transition: Alector announced Neil Berkley's official appointment as CFO effective December 10, 2025, while he continues as CBO, reflecting the company's high regard for his leadership and strategic insight.
- Extensive Experience: With over 20 years in the biotech industry, Berkley has held significant roles in large pharmaceutical and biotech firms, providing Alector with deep support in finance and operations.
- Strategic Priorities: Since joining Alector in 2024, Berkley has played a key role in advancing the company's strategic priorities, strengthening partnerships, and supporting value creation, ensuring robust progress during this critical growth phase.
- Integration of Science and Business: Berkley expressed his commitment to supporting the company's scientific and corporate priorities in neurodegenerative diseases, particularly in advancing promising pipeline products and the development of the ABC platform, aimed at improving patient outcomes and reducing costs.
See More
Alector Appoints Neil Berkley as CFO to Drive Biotech Strategy
- Executive Appointment: Alector announced Neil Berkley's official appointment as Chief Financial Officer (CFO) effective December 10, 2025, after serving as Chief Business Officer (CBO) since March 2024 and Interim CFO since June 2025, reflecting the company's high regard for his leadership capabilities.
- Strategic Leadership: With over 20 years of experience in the biotech sector, Berkley's extensive background in large pharmaceutical and mid-sized biotech firms positions him to effectively drive Alector's strategic priorities in developing therapies for neurodegenerative diseases.
- Financing and Development: Berkley's rich experience in financing, investor engagement, and corporate development will support Alector's key value-creation initiatives, particularly in advancing its promising pipeline and proprietary ABC platform.
- Company Vision: Berkley expressed his commitment to supporting Alector's scientific and corporate priorities, aiming to develop transformative therapies for patients with neurodegenerative diseases, thereby enhancing the company's competitive edge in the market.
See More
Alector Appoints Neil Berkley as CFO
New CFO Appointment: Alector Inc. has announced that Neil Berkley will become the new Chief Financial Officer starting December 10, 2025, while also retaining his role as Chief Business Officer.
Experience and Background: Berkley has over 20 years of experience in corporate strategy, finance, business development, and operations within the biotech and pharmaceutical industries.
Stock Performance: Alector's stock closed at $1.49, reflecting an increase of $0.03 or 2.05 percent on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily represent those of Nasdaq, Inc.
See More
Alector Shares Plunge Nearly 50% Following Phase 3 Trial Failure
- Legal Investigation Initiated: The Schall Law Firm is investigating Alector for potential violations of securities laws, particularly regarding the issuance of false or misleading statements, indicating significant legal risks for the company.
- Poor Clinical Trial Results: Alector's October 21, 2025 press release revealed that its drug candidate, latozinemab, failed to meet the primary clinical endpoint of slowing frontotemporal dementia progression, directly impacting investor confidence in the company's future prospects.
- Stock Price Volatility: Following the disappointing clinical trial results, Alector's shares plummeted nearly 50% the next day, reflecting market pessimism about the company's outlook and raising concerns about its financial health among investors.
- Investor Rights Affected: This incident has drawn attention to the rights of Alector's investors, with the Schall Law Firm urging affected shareholders to participate in the investigation, highlighting potential deficiencies in the company's transparency and information disclosure practices.
See More
ALEC Investors Can Participate in Alector, Inc. Fraud Investigation Led by the Schall Law Firm
Investigation Announcement: The Schall Law Firm is investigating Alector, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors.
Clinical Trial Results: Alector's recent press release revealed that its drug candidate, latozinemab, failed to meet key clinical trial endpoints for treating frontotemporal dementia, leading to a significant drop in the company's stock price.
Investor Impact: Following the announcement of the clinical trial results, Alector's shares plummeted by nearly 50% the day after the news was released.
Legal Support Offer: The Schall Law Firm is offering free consultations to shareholders who may have suffered losses and encourages them to reach out for assistance regarding their rights.
See More
